Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kelun-Biotech TGFBR1 inhibitor series (US20230303562A1)
- Development stage
- Unknown
- Lead developer
- Sichuan Colombotai Biomedical
- Modality
- Small Molecules
01
Overview
Kelun-Biotech TGFBR1 inhibitor series (US20230303562A1): sourced facts only. name: "Pyrazole compound and preparation method therefor and use thereof" [1] target: "relates to a pyrazole compound with TGF beta R1 inhibitory activity" [2] developer: "Sichuan Kelun Biotech Biopharmaceutical Co Ltd" [1] stage: "a disease mediated at least in part by TGF ⁇ R1, such as a cancer or fibrotic disease" [1] modality: "relates to a pyrazole compound with TGF ⁇ R1 inhibitory activity" [1]
02
Targets
TGFBR1
Beyond the preview
Go deeper on Kelun-Biotech TGFBR1 inhibitor series (US20230303562A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kelun-Biotech TGFBR1 inhibitor series (US20230303562A1).